10-K Decoder · All companies

Keros Therapeutics, Inc.

KROS · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$244M$3.55M+6,775%
Operating income$67.6M−$211M
Net income$87.0M−$187M

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026

$Q3 2026Year earlierChange
Revenue$40.0M$14.1M+184%
Operating income$12.8M−$15.4M
Net income$14.2M−$7.30M

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Keros Therapeutics's revenue in FY2025?
$244M in FY2025 (Fiscal year ended Dec 31, 2025), +6,775% vs $3.55M a year earlier, per its 10-K filed Mar 2026.
Was Keros Therapeutics profitable in FY2025?
Yes: net income was $87.0M and operating income $67.6M in FY2025.
What was Keros Therapeutics's revenue in Q3 2026?
$40.0M (+184% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.